Clinical Trial Update: FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial evaluating PCC + Bevacizumab + CA4P vs PCC + Bevacizumab + Placebo for platinum-resistant ovarian cancer was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Platinum-resistant Ovarian Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Combretastatin A-4 phosphate (Combretastatin A-4 phosphate)
• PCC

Snippet

Sponsor: Mateon Therapeutics | Conditions: Platinum Resistant Ovarian Cancer | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2025-03-24